Exelixis, Inc. (LON:0IJO)
45.07
+1.25 (2.85%)
At close: Jun 24, 2025
Exelixis Employees
Exelixis had 1,147 employees as of December 31, 2024. The number of employees decreased by 163 or -12.44% compared to the previous year.
Employees
1,147
Change (1Y)
-163
Growth (1Y)
-12.44%
Revenue / Employee
1.55M GBP
Profits / Employee
434.28K GBP
Market Cap
9.15B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Indivior | 1,051 |
Exelixis News
- 1 day ago - Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment - Seeking Alpha
- 1 day ago - Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - Seeking Alpha
- 1 day ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 1 day ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 1 day ago - AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
- 1 day ago - Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug - Investor's Business Daily
- 2 days ago - Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Business Wire
- 4 days ago - Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire